Senseonics Holdings, Inc.: management transactions · United States · SEC (Form 4)

About Senseonics Holdings, Inc.

Senseonics Holdings, Inc. is a U.S.-based medical technology company listed on the NASDAQ in the United States. Founded in 1996 and headquartered in Germantown, Maryland, the company focuses on the development and commercialization of continuous glucose monitoring (CGM) systems for people with diabetes. Its business model is centered on implantable, long-duration glucose sensors, which gives it a differentiated position within the CGM market relative to more conventional external or frequently replaced sensor systems. ([stockanalysis.com](https://stockanalysis.com/stocks/sens/company/?utm_source=openai)) The company’s core platform is the Eversense franchise, including Eversense E3 and Eversense 365. Senseonics describes these products as long-term implantable CGM systems designed to improve diabetes management through ease of use, accuracy, and continuity of monitoring. In its 2025 annual report, the company noted that following the October 2024 launch of Eversense 365, it saw increased direct-to-consumer leads, stronger patient shipments, and the largest monthly shipment level in company history in December 2025. These data points suggest improving commercial traction, although the company remains in an early stage versus the largest CGM peers. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001616543/000110465926022298/sens-20251231x10k.htm?utm_source=openai)) From a competitive standpoint, Senseonics operates in a market dominated by larger diabetes technology players with broader commercial scale and deeper resources. Its competitive edge is primarily technological and clinical differentiation: an implantable sensor with extended wear duration, a distinct patient experience, and a niche positioning that may appeal to certain patients and providers. At the same time, the company remains a relatively small-cap growth story, with execution risk tied to reimbursement, physician adoption, manufacturing, and sales-force effectiveness. ([stockanalysis.com](https://stockanalysis.com/stocks/sens/company/?utm_source=openai)) Recent developments are particularly relevant for investors. Senseonics said it took over U.S. commercialization and distribution beginning January 1, 2026, a strategic shift that brings the sales and marketing effort in-house. The company’s 2025 filing also points to ongoing European regulatory work for Eversense 365 and continued product momentum after launch. For French-speaking investors, SENS is therefore a NASDAQ-listed U.S. healthcare small cap with attractive long-term thematic exposure to CGM adoption, but with meaningful operational, regulatory, and financing risks that should be monitored closely. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001616543/000110465926022298/sens-20251231x10k.htm?utm_source=openai))